ASTRAZENECA PHARMA INDIA LTD. - 506820 - Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Change In Role Of Senior Management Personnel
Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, we would like to inform you on the change in role of Mr. Amit Bhakri, currently the Business Unit Director - Biopharmaceutical Business Unit. He will be transitioning from the said role with effect from the close of business hours on March 31, 2024, as he takes up another responsibility within AstraZeneca group. Further, we wish to inform you that based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company have approved the appointment of Mr. Ayush Kumar Agarwal as Business Unit Director - Biopharmaceutical Business Unit with effect from April 1, 2024.20-02-2024
